Top Feature

Mar 09, 2017
Pharmaceutical Executive
By Pharmaceutical Executive Editors
Facing mixed market signals, biotech companies look to rise above the fray in advancing new-wave discoveries to the clinical finish line.
Mar 05, 2017
Pharmaceutical Executive
How integrating next-generation sequencing data can advance efforts in immuno-oncology research.
Mar 03, 2017
Pharm Exec speaks to Chris Molloy, CEO of the newly established Medicines Discovery Catapult, which aims to establish new approaches to grow and sustain the UK's reputation for innovative, fast-to-patient drug discovery.
Feb 28, 2017
Pharmaceutical Executive
A panel of biopharma executives responsible for the Latin America business discuss investment, market access, and reimbursement issues in this key regional growth market for the life sciences industry.
Feb 21, 2017
Pharmaceutical Executive
Outlining one country’s unique price-setting model for novel drugs—and the resulting pre-launch strategies for manufacturers.
Feb 21, 2017
Neil Grubert discusses the key trends in market access this year and beyond.
Feb 09, 2017
Pharmaceutical Executive
Keith Bailey offers a new approach to reviving industry collaborations.
Feb 03, 2017
Pharmaceutical Executive
There are question marks when trying to size up the trajectory of the global pharma industry in 2017. One certainty, however, will be change.
Feb 02, 2017
Pharm Exec talks to Mel Formica, Takeda’s VP, Global Market Access, about what he sees as the challenges and opportunities in 2017, and how he envisions the industry's market access capabilities evolving.
Jan 23, 2017
Pharmaceutical Executive
Belén Garijo, CEO of Merck KGaA, Darmstadt, Germany’s healthcare business, shares her approach in transforming a traditional pharma unit focused on small molecules for chronic disease to a high-tech specialty producer of immunotherapy drugs for rare cancers.
native1_300x100
lorem ipsum